Indian companies may be able to make generic copies of Roche's anti-influenza drug Tamiflu with its patent still pending in the country.
Court has barred generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically.
Novartis' threat that it would not introduce new medicines in India after the verdict is hollow, says Anand Grover.
The company had stopped production of generic version of cholesterol lowering drug Lipitor last year as it investigated the issue of potential glass particles in certain lots of the drug.
In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the apex court said on Monday that the drug failed to qualify for a patent according to Indian law.
If it gets the USFDA nod, the sales would help to pull the company out of the red.
Companies run till now by mostly their promoters are increasingly inducting professionals to head their teams.
Expectations of Healthcare sector from Union Budget 2013-14.
'In terms of a great first year, it was an amazing summer and hopefully, I can better that this time... Hopefully, against a side like India, testing yourself against one of the best bowling attacks in world cricket at the moment'
'OPS did not back off.' 'He wanted transparency and he got it.'
The Pradhan Mantri Jan Aushadhi Yojana or PMJAY has not been a runaway success by any yardstick. Not all stores are running, and many are poorly stocked.
Take the rediff business quiz and see how much you know about India's pharmaceutical industry.
It is the first time that the JMI has been placed among the top 10 universities in the (HRD) Ministry's National Institutional Ranking Framework rankings.
Prodded by patent cliff & increasing competition, it files application for foray into injectible oncology segment.
In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the Supreme Court said on Monday that the drug failed to qualify for a patent according to Indian law.
This was not Sharad Pawar or Prithviraj Chavan speaking. It was Uddhav Thackeray, the undisputed chief of the Shiv Sena!
Bayer will not accept a ruling by the Intellectual Property Appellate Board in Chennai on Monday, upholding the compulsory licence granted on March 9 last year and it will appeal against the patent office order at the high court in Mumbai, a spokesperson told PTI.
GVK Biosciences is the latest Indian firm to come under international scrutiny over quality issues.
India's Orchid Chemicals & Pharmaceuticals Ltd said on Monday that US-based Apotex Corporation would sell its generic cephalosporins and other injectible antibiotics in the United States.\n\n\n\n
An interview with Ranbaxy CEO and MD Arun Sawhney on the changes in the past four years and how the company plans to address the US concerns.
The merger has fortified Sun Pharma's position.
Ahmedabad-based Zydus Cadila has made a foray into the US generic formulation segment by setting up a subsidiary Zydus Pharmaceuticals USA, Inc.
In a bid to tap overseas market, Glenmark Pharmaceuticals Ltd's wholly owned US subsidiary has entered into a product development and marketing licence agreement with US-based K V Pharmaceutical Company
These two are now among India's most valuable business houses, ahead of older and more diversified groups, such as the Bajaj, OP Jindal, Anil Ambani, UB, Godrej and Hinduja.
Financial pressure on the parent company triggered the move.
Demand will boom in the US and China, but exporters say it will be difficult for India to tap these markets.
The Indian pharmaceutical players have the potential to corner about 25 per cent of the generic market amounting to $3.75 billion by 2007-08 through leveraging their low cost and technology advantage, according to Rabo India Finance report.
Lupin will be launching the generic version of Yasmin, a brand of Bayer Healthcare.
US election results may not reverse Indian markets' bearish trend, says Devangshu Datta
It was in 2005, India changed its patent law and started granting patents in medicines.
Drug major Ranbaxy Laboratories on Thursday said it plans to launch more generic products in the US market with possible marketing exclusivity, while keeping options open for overseas acquisitions to grow its business in various global markets.
The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
In 2012, drugs worth $35 billion went off-patent in the US, while the market size of drugs which will see patent expiry in 2013 will halve to $17 billion.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances